Core Viewpoint - The company, Boshi Co., Ltd. (002698), has made significant investments in three advanced medical robotic projects, emphasizing the importance of artificial intelligence in enhancing accuracy and efficiency in surgical procedures [1] Group 1: Investment Projects - The company has invested in three key projects: 1. Harbin Sizerui Intelligent Medical Equipment Co., Ltd. for minimally invasive laparoscopic surgical robots 2. Jiangsu Ruil Medical Technology Co., Ltd. for stereotactic radiosurgery robots 3. Suzhou Zhuzheng Robotics Co., Ltd. for remote-assisted pedicle screw implantation robots [1] - These projects are part of the company's strategy in the high-end medical diagnostic and therapeutic equipment sector [1] Group 2: Communication and Disclosure - The company encourages investors to refer to its 2025 semi-annual report for detailed information on investments in the high-end medical diagnostic and therapeutic equipment sector [1] - The company will disclose significant information through regular reports or temporary announcements as required [1]

Core Viewpoint - Citi has released a report indicating that MicroPort Robotics-B (02252) has issued a strong positive profit forecast for the fiscal year 2025, projecting a revenue growth of 110% to 120%, surpassing Citi's expectation of 100% and the market's expectation of 94% [1] Group 1: Company Performance - The key highlight is the revenue exceeding expectations, confirming that the company is in a phase of rapid global business expansion, which is crucial for investors [1] - The momentum is primarily driven by the overseas orders for the "TUMAI" robot, which are expected to exceed 100 units in fiscal year 2025, surpassing the previous guidance of 70 to 80 units provided in August [1] Group 2: Market Reaction and Policy Impact - The market reacted positively on January 21 to the newly released "Guidelines for the Establishment of Pricing Projects for Pathological Medical Services (Trial)," leading to a rise in the stock prices of MicroPort Robotics and its peers [1] - This policy is viewed as a milestone that reduces the risks associated with commercialization pathways and provides a clear and unified framework for industry growth [1]

为减轻患者医疗负担，推动医疗机器人技术发展，近年来，北京、上海、湖南、广东等省市陆续将手术机器人及相关耗材等项目纳入医保支付范 围。比如北京医保规定，机器人手术费用报销限额为8000元，也就是说在8000元的范围内可以全额报销。而一次性耗材医保可报销70%。纳入医保 之后，机器人手术的个人自费部分由之前的3万元-4万元下降到1万元左右。 转载请注明央视财经 编辑：潘煦 国家医保局从立项、定价等方面入手，畅通新技术的收费通道，助力满足临床急需的新技术新产品加快收益回报。目前已公布的37批立项指南新 增涉及新产品新技术的价格项目100多项，基本形成"价格立项与技术创新并行"的格局。比如：神经系统类立项指南统一设立"脑机接口置入费""脑 机接口适配费"等价格项目，助推脑机接口技术快速进入临床应用并收费。 （央视财经《正点财经》）截至目前，我国已先后发布37批医疗服务价格项目立项指南，新增100多项与医疗新技术相关的价格项目。2026年国家 医保局还将完成3批医疗服务价格项目立项指南编制工作。 ...

来源：科技日报 新研发的自主机器人系统可在微米级尺度上稳定执行插管任务，确保针头准确进入目标血管，同时最大 限度避免组织损伤。研究显示，在静止眼球中，机器人成功插管的比例达90%；在动态模拟条件下仍保 持83%的成功率。尤为关键的是，系统能可靠识别针尖何时接触并顺利进入静脉。 该系统配备两个专用于眼部微创手术的机器人，分别持针与操作工具。硬件上集成了3种深度学习模 型，经训练后能实时追踪针尖运动、识别解剖结构，并自主规划最优路径，确保精准穿刺。目前，团队 已在离体猪眼上开展测试，部分实验还模拟了活体呼吸带来的周期性眼球微动。 团队表示，视网膜静脉插管术所需的操控精度须小于100微米，远超人类手部生理能力。这一突破表 明，借助机器人与人工智能，最精细的眼科手术已可实现部分自动化，且具备安全性、准确性与可复制 性。但要真正应用于临床，还需进一步在活体动物及人体试验中验证其有效性与安全性。（科技日报记 者 刘霞） 美国约翰斯·霍普金斯大学科学家研发出一款新型自主机器人系统，有望精准完成视网膜静脉插管术， 为治疗严重眼疾开辟新路径。该研究在先进的机器人控制技术基础上，融合了高分辨率成像技术与深度 学习算法，展现出卓越 ...

Core Insights - The market share of domestic surgical robots in China has increased from 32.61% in 2023 to 48.89% in 2024, indicating significant growth in the sector [1] - Despite advancements, the utilization rate of robots in surgeries in China is only 6.33%, compared to 42% in the United States, highlighting room for improvement in the clinical application of surgical robots [1] Group 1: Changes in Pricing Logic - The previous pricing model for surgical robots was based on factors like surgical approach and brand, leading to unclear charges and increased patient burden [2] - The new guidelines introduce three pricing categories: navigation, participation in execution, and precise execution, allowing for a more transparent and fair pricing structure [2] - This "pay for performance" approach rewards robots that demonstrate higher participation and clinical value, potentially excluding less effective products from benefiting financially [2] Group 2: Clinical Value and Market Recognition - The guidelines acknowledge the clinical value of surgical robots, which may shorten the adoption cycle for new technologies and enhance market recognition for self-developed products [3] - Companies like Shenzhen Precision Medical Technology have successfully completed over 14,000 clinical surgeries with their robotic systems, reinforcing the importance of clinical validation [3] Group 3: Expansion of Precision Surgery - The guidelines aim to broaden the application of precision surgeries by enabling remote surgical assistance, which can be particularly beneficial for patients in remote areas [4] - The introduction of a "remote surgical assistance fee" will facilitate the use of surgical robots in telemedicine, allowing experts in resource-rich areas to assist patients elsewhere [4] - The national health authority plans to unify medical service pricing across the country, ensuring access to high-quality and affordable medical services for the public [4]

Group 1 - The core achievement of Beijing Changmugu Medical Technology Co., Ltd. includes covering 30 provincial-level administrative regions and over 200 major cities, with thousands of top-tier hospitals served and tens of thousands of patients treated during the "14th Five-Year Plan" period [1] - The company has developed the ROPA orthopedic intelligent surgical robot, which has become a "star product" due to its technological innovation, filling a gap in artificial intelligence within the orthopedic surgical robot field [1] - The rapid development of the company is supported by the robust industrial foundation and talent pool in Beijing E-Town, which provides comprehensive development support through various measures including policy support and innovation resources [1] Group 2 - The "14th Five-Year Plan" is seen as a period of explosive technological innovation, with Changmugu successfully integrating "AI + robotics" to create a systematic orthopedic intelligent solution, promoting the ROPA robot for large-scale clinical application [2] - Looking forward to the "15th Five-Year Plan," the company aims to enhance the accessibility and standardization of medical services by promoting high-end intelligent medical equipment in clinical settings, especially in grassroots medical institutions [2] - The company plans to continue deepening the integration of artificial intelligence and surgical robot technology, fostering a more open and collaborative industrial ecosystem, while also seeking international cooperation for broader recognition of Chinese smart medical solutions [2]

Core Viewpoint - The company, Boshi Co., has made significant investments in high-end medical diagnostic and therapeutic equipment, focusing on three key projects in the field of robotic surgery [2] Investment Projects - The company and its wholly-owned subsidiary have invested in three projects: 1. Harbin Sizerui Intelligent Medical Equipment Co., Ltd. for a minimally invasive laparoscopic surgical robot project 2. Jiangsu Ruil Medical Technology Co., Ltd. for a stereotactic radiosurgery robot project 3. Suzhou Zhuzheng Robot Co., Ltd. for a remote-assisted pedicle screw minimally invasive implantation robot project [2] - Detailed information can be found in the company's 2025 semi-annual report on page 29 under "Investment in High-end Medical Diagnostic and Therapeutic Equipment" [2]

Core Viewpoint - The company, Boshi Co., has confirmed its involvement in the surgical robotics sector through investments in three key projects related to high-end medical diagnostic and therapeutic equipment [1]. Group 1: Company Involvement in Surgical Robotics - Boshi Co. has invested in three projects in the surgical robotics field: 1. Harbin Sizhe Rui Intelligent Medical Equipment Co., Ltd. focusing on minimally invasive laparoscopic surgical robots 2. Jiangsu Ruil Medical Technology Co., Ltd. working on stereotactic radiosurgery robots 3. Suzhou Zhuzheng Robotics Co., Ltd. developing remote-assisted minimally invasive implantation robots [1]. - The details of these investments can be found in the company's 2025 semi-annual report, specifically on page 29 under the section "Investment in High-end Medical Diagnostic and Therapeutic Equipment" [1].

Group 1: Core Insights - Elon Musk predicts that General Artificial Intelligence (AGI) will arrive by 2026, with robots surpassing human surgical skills within three years and achieving complete superiority over human surgeons in four years [1][2] - The medical community expresses skepticism about the feasibility of achieving fully autonomous surgical robots within the proposed timeline, emphasizing the need for significant advancements and a longer timeframe for such technology to be realized [1][7][8] Group 2: Technological Developments - Neuralink, Musk's brain-machine interface company, is already utilizing robots for "brain insertion" surgeries, with over 10,000 patients reportedly waiting for procedures [3] - The surgical robots developed by Neuralink have significantly improved efficiency, reducing the time to implant a single electrode from 17 seconds to 1.5 seconds, with the goal of making surgeries quick enough to be completed during a lunch break [3][4] Group 3: Market Dynamics - The surgical robot market in China is experiencing rapid growth, with significant investments and a competitive landscape emerging, particularly in the context of IPOs and funding rounds [9][10] - The market for vascular interventional surgical robots is projected to reach 5.824 billion RMB by 2030, with a compound annual growth rate of 90% [12] Group 4: Industry Perspectives - Experts in the medical field believe that while robots may enhance surgical efficiency, the complete replacement of human surgeons is not imminent, and the role of doctors will evolve rather than disappear [7][8] - The introduction of new pricing guidelines by the National Healthcare Security Administration is expected to positively impact the adoption and commercialization of surgical robots [11][12]

Financing Information - The company "Muguang Medical" has completed a Pre-A round financing of nearly 30 million yuan [6] - Investors include Huihe Asset and Xiamen Heguang Tongchuang [6] - The funds will be primarily used for product registration, accelerating the development of robots in research, and marketing existing products [6] Company Overview - Founded in 2023 and based in Chengdu, Sichuan Province, Muguang Medical focuses on developing the world's first intelligent robot for ocular imaging [8] - The company addresses clinical challenges faced by newborns, elderly individuals, and disabled persons who struggle with existing optical coherence tomography (OCT) devices [8] - The intelligent robot has received national medical device registration and multiple patents, offering a unique advantage in the market [8] Market Potential - Muguang Medical's intelligent ocular imaging robot breaks the limitations of traditional OCT devices, expanding its application to various medical settings such as outpatient clinics, hospital wards, and community health [10] - The robot's capabilities allow it to cater to low-cooperation populations, significantly increasing the potential service user base [10] - The device supports a full cycle of eye disease management, enhancing its role from diagnosis to treatment [10] Team Background - The founding team consists of high-level overseas talents from top universities, including the University of Electronic Science and Technology of China and Washington University in St. Louis [12] - The company aims to lead the global transformation of medical intelligence through its innovative approach combining academia and industry [12] Product Innovation - The intelligent ocular imaging robot allows for non-contact, fully automated imaging, significantly reducing the need for patient cooperation [15] - The device can perform eye examinations in various positions and conditions, making it suitable for infants and patients with mobility issues [15] - It features advanced 3D vision and tracking algorithms, enabling quick and efficient imaging within 10 seconds [16] Future Plans - Muguang Medical plans to initiate a larger A round financing next year, targeting several hundred million yuan to support the development of new medical devices [17] - The company has already accumulated clinical data since 2022, providing a competitive edge in the market [17] Investor Insights - Investors recognize the growing potential in the medical robotics field, particularly in ophthalmology, and highlight the team's strong commercialization capabilities [19] - The intelligent ocular imaging robot is expected to provide significant social and economic value, especially for elderly and visually impaired patients [19][20]